Catalysts for Blincyto
25 tracked
Apr 30, 2026
phase 1 2 completion
AbbVie Inc — blinatumomab (Phase I/II Trial Completion)
blinatumomab
→
Apr 25, 2026
phase 2 completion
Soochow University Hospital 1 — blinatumomab (Phase II Trial Completion)
blinatumomab
→
Oct 21, 2025
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 29, 2025
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 17, 2024
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 14, 2024
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 8, 2024
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 5, 2022
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 18, 2022
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 20, 2020
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 10, 2018
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 29, 2018
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Nov 30, 2017
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jul 11, 2017
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
May 3, 2017
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 3, 2014
approval
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→